Lacerta Therapeutics

Lacerta Therapeutics is a clinical-stage gene therapy company developing treatments for central nervous system and lysosomal storage diseases using a range of proprietary adeno-associated virus (AAV) vector technologies. Lacerta Therapeutics is committed to discovering and developing AAV-based therapies by leveraging our proprietary AAV capsid technology platform and proprietary scalable manufacturing platform across three modalities: gene replacement, vectored antibodies, and vectored microRNA modulation, targeting new therapies for central nervous system and lysosomal storage diseases.